U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Elevated urinary succinylacetone level

MedGen UID:
1053324
Concept ID:
CN377430
Finding
HPO: HP:6000598

Definition

Presence in the urine of succinylacetone, which is one of the toic block metabolites formed in tyrosinaemia type 1 because of a defect in the final enzyme of the pathway of the degradation of tyrosine, namely fumarylacetoacetase (FAH, EC 3.7.1.2). [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVElevated urinary succinylacetone level

Conditions with this feature

Tyrosinemia type I
MedGen UID:
75688
Concept ID:
C0268490
Disease or Syndrome
Untreated tyrosinemia type I usually presents either in young infants with severe liver involvement or later in the first year with liver dysfunction and renal tubular dysfunction associated with growth failure and rickets. Untreated children may have repeated, often unrecognized, neurologic crises lasting one to seven days that can include change in mental status, abdominal pain, peripheral neuropathy, and/or respiratory failure requiring mechanical ventilation. Death in the untreated child usually occurs before age ten years, typically from liver failure, neurologic crisis, or hepatocellular carcinoma. Combined treatment with nitisinone and a low-tyrosine diet has resulted in a greater than 90% survival rate, normal growth, improved liver function, prevention of cirrhosis, correction of renal tubular acidosis, and improvement in secondary rickets.

Recent clinical studies

Etiology

Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ
J Inherit Metab Dis 2013 Jan;36(1):15-20. Epub 2012 Mar 29 doi: 10.1007/s10545-012-9482-1. PMID: 22456946

Diagnosis

Medina MF, Arias C, Cabello JF, De la Parra A, Valiente A, Castro G, Fuenzalida K, Cornejo V
Am J Med Genet C Semin Med Genet 2020 Dec;184(4):1009-1013. Epub 2020 Dec 10 doi: 10.1002/ajmg.c.31863. PMID: 33300677
Liu Y, Luo Y, Xia L, Qiu BJ, Zhou T, Feng MX, Xue F, Chen XS, Han LS, Zhang JJ, Xia Q
J Dig Dis 2020 Mar;21(3):189-194. Epub 2020 Feb 25 doi: 10.1111/1751-2980.12846. PMID: 31953907
Choi HJ, Bang HI, Ki CS, Lee SY, Kim JW, Song J, Shin MR, Lee YW, Lee DH, Park HD
Ann Clin Lab Sci 2014 Summer;44(3):317-23. PMID: 25117105
Karnik D, Thomas N, Eapen CE, Jana AK, Oommen A
Indian J Pediatr 2004 Oct;71(10):929-32. doi: 10.1007/BF02830839. PMID: 15531838
Kvittingen EA, Jellum E, Stokke O, Flatmark A, Bergan A, Sødal G, Halvorsen S, Schrumpf E, Gjone E
J Inherit Metab Dis 1986;9(2):216-24. doi: 10.1007/BF01799465. PMID: 3091928

Therapy

Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ
J Inherit Metab Dis 2013 Jan;36(1):15-20. Epub 2012 Mar 29 doi: 10.1007/s10545-012-9482-1. PMID: 22456946
Kvittingen EA, Jellum E, Stokke O, Flatmark A, Bergan A, Sødal G, Halvorsen S, Schrumpf E, Gjone E
J Inherit Metab Dis 1986;9(2):216-24. doi: 10.1007/BF01799465. PMID: 3091928

Clinical prediction guides

Liu Y, Luo Y, Xia L, Qiu BJ, Zhou T, Feng MX, Xue F, Chen XS, Han LS, Zhang JJ, Xia Q
J Dig Dis 2020 Mar;21(3):189-194. Epub 2020 Feb 25 doi: 10.1111/1751-2980.12846. PMID: 31953907
Kvittingen EA, Jellum E, Stokke O, Flatmark A, Bergan A, Sødal G, Halvorsen S, Schrumpf E, Gjone E
J Inherit Metab Dis 1986;9(2):216-24. doi: 10.1007/BF01799465. PMID: 3091928
Tuchman M, Freese DK, Sharp HL, Whitley CB, Ramnaraine ML, Ulstrom RA, Najarian JS, Ascher N, Buist NR, Terry AB
J Inherit Metab Dis 1985;8(1):21-4. doi: 10.1007/BF01805479. PMID: 2581063

Supplemental Content

Table of contents

    Clinical resources

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...